



22 October 2020

Company Announcements Office
ASX Limited

Dear Sir/Madam

Actinogen Medical Limited
Cleansing Notice under section 708A of the Corporations Act 2001 (Cth)

On 15 October 2020, **Actinogen Medical Limited** ACN 086 778 476 (ASX:ACW) (**Actinogen** or the **Company**) announced that it had received commitments for a \$6 million private placement of shares at 2.2 cents per share (being 272,727,273 million fully paid ordinary shares in the Company) to various sophisticated and institutional investors introduced by Bell Potter Limited (**Placement**).

Actinogen gives this cleansing notice (**Notice**) under section 708A(5)(e) of the *Corporations Act 2001 (Cth)* (**Corporations Act**). The Placement Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act on 22 October 2020.

As at the date of this Notice, the Company has complied with:


- the provisions of Chapter 2M of the Corporations Act as they apply to Actinogen; and
- section 674 of the Corporations Act.

As at the date of this Notice, there is no excluded information for the purposes of section 708A(7) and section 708A(8) of the Corporations Act.

Yours faithfully

A handwritten signature in black ink, appearing to read "Peter Webse", is written over a light blue horizontal line.

Peter Webse
Company Secretary

Actinogen Medical
Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
 @BillKetelbey

Investor Enquiries
Miranda Newnham
Vesparum Capital
P: +61 3 8582 4800
E: actinogen@vesparum.com

Authorised by the Board of Directors of Actinogen Medical